<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">J Enzyme Inhib Med Chem</span><span class="iso-abbrev" title="iso-abbrev">J Enzyme Inhib Med Chem</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Journal of Enzyme Inhibition and Medicinal Chemistry</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">1475-6366</span><span class="issn-epub" tagx="issn" title="issn-epub">1475-6374</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">Taylor &amp;amp; Francis</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7801109">7801109</a></span><span class="pmid" title="pmid"> pmid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/33406941">33406941</a></span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1080/14756366.2020.1868450">10.1080/14756366.2020.1868450</a></span><span class="publisher-id" title="publisher-id">1868450</span><div class="unknown" title="article-version" tag="article-version">
Version of Record</div> <div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Research Article</span>: <span class="subject" title="subject">Research Paper</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Development of novel isatinâ€"nicotinohydrazide hybrids with potent activity against susceptible/resistant <i>Mycobacterium tuberculosis</i> and bronchitis causingâ€"bacteria</div> <div class="alt-title" title="alt-title">
Z. M. Elsayed et al.</div> <div class="alt-title" title="alt-title">
Journal of Enzyme Inhibition and Medicinal Chemistry</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Elsayed</span><span class="given-names" tagx="given-names" title="given-names">Zainab M.</span></span><a href="#AF0001">a</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">Wagdy M.</span></span><a href="#AF0001">a</a><a href="#AF0002">b</a><a href="#AN0001" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdel-Aziz</span><span class="given-names" tagx="given-names" title="given-names">Marwa M.</span></span><a href="#AF0003">c</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El Hassab</span><span class="given-names" tagx="given-names" title="given-names">Mahmoud A.</span></span><a href="#AF0004">d</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Elkaeed</span><span class="given-names" tagx="given-names" title="given-names">Eslam B.</span></span><a href="#AF0005">e</a><a href="#AF0006">f</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Warhi</span><span class="given-names" tagx="given-names" title="given-names">Tarfah</span></span><a href="#AF0007">g</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdel-Aziz</span><span class="given-names" tagx="given-names" title="given-names">Hatem A.</span></span><a href="#AF0008">h</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abou-Seri</span><span class="given-names" tagx="given-names" title="given-names">Sahar M.</span></span><a href="#AF0009">i</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mohammed</span><span class="given-names" tagx="given-names" title="given-names">Eman R.</span></span><a href="#AF0009">i</a></span><span class="citation_author_institution" id="AF0001">[a], <span class="institution" title="institution">Faculty of Pharmacy, Scientific Research and Innovation Support Unit, Kafrelsheikh University</span><span class="city" tagx="city" title="city">Kafrelsheikh</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0002">[b], <span class="institution" title="institution">Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Kafrelsheikh University</span><span class="city" tagx="city" title="city">Kafrelsheikh</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0003">[c], <span class="institution" title="institution">The Regional Center for Mycology &amp;amp; Biotechnology, Al-Azhar University</span><span class="city" tagx="city" title="city">Cairo</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0004">[d], <span class="institution" title="institution">Department of Pharmaceutical Chemistry, School of Pharmacy, Badr University in Cairo</span><span class="city" tagx="city" title="city">Badr City</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0005">[e], <span class="institution" title="institution">Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University</span><span class="city" tagx="city" title="city">Ad Diriyah</span><span class="country" tagx="country" title="country">Saudi Arabia</span></span><span class="citation_author_institution" id="AF0006">[f], <span class="institution" title="institution">Faculty of Pharmacy (Boys), Department of Pharmaceutical Organic Chemistry, Al-Azhar University</span><span class="city" tagx="city" title="city">Cairo</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0007">[g], <span class="institution" title="institution">Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University</span><span class="city" tagx="city" title="city">Riyadh</span><span class="country" tagx="country" title="country">Saudi Arabia</span></span><span class="citation_author_institution" id="AF0008">[h], <span class="institution" title="institution">Department of Applied Organic Chemistry, National Research Center</span><span class="city" tagx="city" title="city">Giza</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0009">[i], <span class="institution" title="institution">Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Cairo University</span><span class="city" tagx="city" title="city">Cairo</span><span class="country" tagx="country" title="country">Egypt</span></span></div> <div class="author-notes" title="author-notes"> <div class="fn-type-" title=""> <p content-type="appended text">Supplemental data for this article can be accessed <a href="https://doi.org/10.1080/14756366.2020.1868450"><u>here</u></a>.</p> </div> <div class="corresp" title="corresp"><b>CONTACT</b> Wagdy M. Eldehna <span class="email" tagx="email" title="email">wagdy2000@gmail.com</span><span class="institution" title="institution">Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Kafrelsheikh University</span>, <span class="addr-line" title="addr-line">P.O. Box 33516</span>, <span class="city" tagx="city" title="city">Kafrelsheikh</span>, <span class="country" tagx="country" title="country">Egypt</span></div> </div><span class="pub-date-" title="pub-date-">: <span>2021-1-1</span></span><span class="pub-date-" title="pub-date-">: <span>2021</span></span><span class="volume" tagx="volume" title="volume">36</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">384</span><span class="lpage" tagx="lpage" title="lpage">393</span><div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">The Author(s)</span>, <span class="copyright-year" tagx="copyright-year" title="copyright-year">2021</span></span><span class="license" title="license"><span class="license-p" title="license-p">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</span></span></div><a class="self-uri" href="IENZ_36_1868450.pdf" title="self-uri">IENZ_36_1868450.pdf</a><div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <div class="title" tagx="title" title="title">
Abstract</div> <p>Joining the global fight against Tuberculosis, the world's most deadly infectious disease, herein we present the design and synthesis of novel isatin-nicotinohydrazide hybrids (<b>5aâ€"m</b> and <b>9aâ€"c</b>) as promising anti-tubercular and antibacterial agents. The anti-tubercular activity of the target hybrids was evaluated against drug-susceptible M. tuberculosis strain (ATCC 27294) where hybrids <b>5d</b>, <b>5g</b> and <b>5h</b> were found to be as potent as INH with MIC = 0.24 Âµg/mL, also the activity was evaluated against Isoniazid/Streptomycin resistant M. tuberculosis (ATCC 35823) where compounds <b>5g</b> and <b>5h</b> showed excellent activity (MIC = 3.9 Âµg/mL). Moreover, the target hybrids were examined against six bronchitis causing-bacteria. Most derivatives exhibited excellent antibacterial activity. K. pneumonia emerged as the most sensitive strain with MIC range: 0.49â€"7.81 Âµg/mL. Furthermore, a molecular docking study has proposed DprE1 as a probable enzymatic target for herein reported isatin-nicotinohydrazide hybrids, and explored the binding interactions within the vicinity of DprE1 active site.</p> </div> <div class="abstract" title="abstract"> <div class="title" tagx="title" title="title">
GRAPHICAL ABSTRACT</div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/" /></div>  </div> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Keywords</div> <div class="kwd" title="kwd">
Anti-tubercular activity</div> <div class="kwd" title="kwd">
DprE1 inhibitors</div> <div class="kwd" title="kwd">
resistant TB</div> <div class="kwd" title="kwd">
nicotinohydrazide</div> <div class="kwd" title="kwd">
isatin derivatives</div> </div> <div class="counts" title="counts"><span class="fig-count" title="fig-count">fig-count: </span><span class="table-count" title="table-count">table-count: </span><span class="page-count" title="page-count">page-count: </span><span class="word-count" title="word-count">word-count: </span></div> </div> </div> <div class="body" title="body"> <div class="intro" title="intro"><span class="label" tagx="label" title="label">1.</span><div class="title" tagx="title" title="title">
Introduction</div> <p>Tuberculosis (TB) is considered to be the worldâ€™s top infectious killer<a href="#CIT0001"><sup>1</sup></a>. It is a complicated devastating disease that accounts for the death of 1.5 million individuals in 2018 as declared by WHO<a href="#CIT0001"><sup>1</sup></a>. About 23% of the worldâ€™s population is expected to be latent TB carriers with a high risk to develop the disease<a href="#CIT0002"><sup>2</sup></a>. The first-line drugs such as Isoniazid, Rifampicin, Ethambutol, and Streptomycin have shown significant activity against <i>Mycobacterium tuberculosis</i> however, the emergency of drug-resistant TB (DR-TB), especially multi-drug resistant TB (MDR-TB) is still a serious trouble<a href="#CIT0003"><sup>3</sup></a>. The emerged drug resistance can be considered as a global health crisis, where only one out of three accessing proper remedy among the patients falling ill in 2018<a href="#CIT0001"><sup>1</sup></a>.</p> <p>Along with the emerged drug resistance, the development of secondary bacterial infection is considered to be a critical problem<a href="#CIT0004"><sup>4</sup></a>. Different bacterial strains have been isolated from sputum samples including: <i>Haemophilus influenzae</i>, <i>Klebsiella pneumoniae</i>, <i>Streptococcus pneumoniae</i>, and <i>Moraxella catarrhalis</i><a href="#CIT0004"><sup>4</sup></a><sup>,</sup><a href="#CIT0005"><sup>5</sup></a>. The tubercular and the bacterial co-infection can lead to inadequate treatment causing serious complications such as pneumoniae, bronchial anthracofibrosis, and chronic airflow obstruction<a href="#CIT0005"><sup>5â€"8</sup></a>. Unfortunately, many virulent bacterial strains have developed bacterial resistance against most of the currently used antibiotics. The death rate due to bronchitis has been increased up to an alarming level recording about 0.7 million cases of death every year. Thus, there is a crucial need to design and synthesise new candidates that may help in the battle of the developed bacterial resistance towards the currently available anti-tubercular and antibacterial drugs.</p> <p>Isatin is a promising endogenous biologically active scaffold. It could be chemically modified to produce various heterocyclic compounds with different biological activities<a href="#CIT0009"><sup>9â€"14</sup></a>. Isatin based derivatives have revealed promising antibacterial<a href="#CIT0015"><sup>15â€"17</sup></a> and anti-TB effects<a href="#CIT0018"><sup>18</sup></a><sup>,</sup><a href="#CIT0019"><sup>19</sup></a>. Moreover, the nicotinohydrazide moiety has a large contribution to the field of medicinal chemistry. It has been incorporated in several active antimicrobial<a href="#CIT0020"><sup>20</sup></a> and anti-tubercular agents<a href="#CIT0021"><sup>21</sup></a>. In fact, the presence of a hydrazide group can be considered as a significant key for an optimum anti-tubercular activity<a href="#CIT0022"><sup>22</sup></a>. Recently, several research teams adopted molecular hybridisation techniques between isatin and different moieties for the design of new anti-mycobacterial agents<a href="#CIT0023"><sup>23â€"26</sup></a>, such as isatin-INH hybrids <b>I</b> (<a href="#F0001">Figure 1</a>)<a href="#CIT0025"><sup>25</sup></a> and isatin-nalidixic acid hybrids <b>II</b> (<a href="#F0001">Figure 1</a>)<a href="#CIT0026"><sup>26</sup></a>. Later, our research team has identified the <i>N</i>-substituted isatin-thiazolidinone hybrid <b>III</b> (<a href="#F0001">Figure 1</a>) as a promising antitubercular agent that produced an effective killing of <i>M. aurum</i> in infected macrophage model with broad-spectrum antimicrobial effect against sensitive and resistant bacterial strains<a href="#CIT0027"><sup>27</sup></a>. SAR study revealed that <i>N</i>-benzylation or <i>N</i>-methylation of the 2-oxindole ring enhanced the activity by 2-4 folds as compared to the <i>N</i>-unsubstituted analogues.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 1.</span></a></div>   <p>Structures of some reported isatin-based anti-mycobacterial agents (<b>Iâ€"III</b>).</p>   </div> <p>In view of the findings stated above and in a continuation of our previous work for the discovery of potential anti-tubercular and anti-microbial agents<a href="#CIT0028"><sup>28</sup></a>, we decided to extend our research through conjugating different <i>N</i>-substituted isatin moieties with a nicotinohydrazide moiety to furnish target hybrids <b>5a-I</b> (<a href="#F0002">Figure 2</a>). In order to explore the impact of C-5 substitution, as well as to ensure different lipophilic environments that may be suitable for the mycobacterial activity, both 5-Cl and 5-Br substituents were grafted at isatin scaffold. As it was suggested that <i>N</i>-substitution of isatin scaffold could enhance the mycobacterial activity<a href="#CIT0027"><sup>27</sup></a><sup>,</sup><a href="#CIT0029"><sup>29</sup></a>, <i>N</i>-alkylation, or <i>N</i>-benzylation of the herein reported hybrids was performed (<a href="#F0002">Figure 2</a>). Thereafter, the impact of C-2 and C-6 substitution of the nicotinohydrazide moiety the anti-tubercular and antibacterial activities were investigated through developing the two sets <b>5jâ€"m</b> and <b>9aâ€"c</b> (<a href="#F0002">Figure 2</a>). Finally, an isatin-3-pyridylamine hybrid <b>14</b> was synthesised to carry out further elaboration of the target scaffold (<a href="#F0002">Figure 2</a>).</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 2.</span></a></div>   <p>Design of the target hybrids <b>5aâ€"m</b>, <b>9aâ€"c</b>, and <b>14</b>.</p>   </div> <p>Herein seventeen new 2-oxindolin-3-ylidene-nicotinohydrazide derivatives (<b>5aâ€"m</b>, <b>9aâ€"c</b>, and <b>14</b>) were designed, synthesised, and evaluated for their anti-tubercular activity against drug-susceptible <i>M. tuberculosis</i> strain (ATCC 27294) and Isoniazid/Streptomycin resistant <i>M. tuberculosis</i> (ATCC 35823), together with the antibacterial effect against bronchitis causing-bacteria in an attempt to produce new candidates having potential activities with minimal bacterial resistance that may reduce the complications associated with the secondary bacterial infection.</p> <p>Finally, molecular docking studies have been performed for the most active compounds into the active sites of two enzymes: flavoenzyme Decaprenylphosphoryl-<i>Î²</i>-D-Ribose 2â€²-Epimerase (DprE1) and enoyl-acyl carrier protein reductase (InhA) being critical enzymes in the metabolism and synthesis of <i>M. tuberculosis</i> cell wall<a href="#CIT0030"><sup>30</sup></a><sup>,</sup><a href="#CIT0031"><sup>31</sup></a> to explore the possible mechanism of action of the new hybrids.</p> </div> <div class="results" title="results"><span class="label" tagx="label" title="label">2.</span><div class="title" tagx="title" title="title">
Results and discussion</div> <div class="chemistry" title="sec"><span class="label" tagx="label" title="label">2.1.</span><div class="title" tagx="title" title="title">
Chemistry</div> <p>The synthetic strategies adopted for the preparation of final compounds (<b>5aâ€"m</b>, <b>9aâ€"c</b> and <b>14</b>) were illustrated in <a href="#SCH0001 SCH0002 SCH0003">Schemes 1â€"3</a>. In the first scheme, different isatin derivatives <b>3aâ€"c</b> were alkylated with the appropriate alkyl halide in anhydrous DMF in the presence of K<sub>2</sub>CO<sub>3</sub> as an acid binder to furnish the <i>N</i>-substituted indoline-2,3-diones <b>4aâ€"i</b>. On the other hand, methyl nicotinate <b>1a</b> and methyl 6-methoxynicotinate <b>1b</b> was refluxed with hydrazine hydrate in methanol to produce the key intermediate nicotinohydrazides <b>2aâ€"b</b> which subsequently reacted with <i>N</i>-substituted indoline-2,3-dione derivatives <b>4aâ€"i</b> in absolute ethanol containing a catalytic amount of glacial acetic acid to get the final compounds <b>5aâ€"m</b> (<a href="#SCH0001">Scheme 1</a>).</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Scheme 1.</span></a></div>   <p>Synthesis of target isatin hybrids <b>5aâ€"m</b>; (<b>i</b>) NH<sub>2</sub>NH<sub>2</sub>.H<sub>2</sub>O/methanol/reflux 4â€‰h, (<b>ii</b>) R<sub>1</sub>-Br/DMF/KI (Cat.)/K<sub>2</sub>CO<sub>3</sub>/reflux 3â€‰h, (<b>iii</b>) Ethanol absolute/drops glacial acetic acid (Cat.)/reflux 6â€‰h.</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Scheme 2.</span></a></div>   <p>Synthesis of target isatin hybrids <b>9aâ€"c</b>; (<b>i</b>) ethyl acetoacetate/NH<sub>4</sub>OAc/glacial acetic acid/reflux 6â€‰h, (<b>ii</b>) NH<sub>2</sub>NH<sub>2</sub>.H<sub>2</sub>O/methanol/reflux 6â€‰h, (<b>iii</b>) Ethanol absolute/drops glacial acetic acid (Cat.)/reflux 6â€‰h.</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Scheme 3.</span></a></div>   <p>Synthesis of target compound <b>14</b>; (<b>i</b>) NaOH/MeOH/reflux 6â€‰h, (<b>ii</b>) SOCl<sub>2</sub>/reflux 4â€‰h, (<b>iii</b>) NaN<sub>3</sub>/acetone/stirring at R.T. 4â€‰h, (<b>iv</b>) Dry toluene/reflux 1â€‰h, (<b>v</b>) Dry toluene/reflux 5â€‰h.</p>   </div> <p>In the second scheme, 3-(dimethylamino)-1-phenylprop-2-en-1-one <b>6</b> was heated under reflux with ethyl acetoacetate and NH<sub>4</sub>OAc in glacial acetic acid to produce ethyl 2-methyl-6-phenylnicotinate <b>7</b> in which, the ester moiety was subjected to hydrazinolysis to produce the key intermediate 2-methyl-6-phenylnicotinohydrazide <b>8</b> which reacted with different <i>N</i>-substituted indoline-2,3-diones <b>4aâ€"c</b> to get target compounds <b>9aâ€"c</b>.</p> <p>In the last scheme, methyl 6-methoxynicotinate <b>1b</b> was refluxed with NaOH in MeOH to get the free 6-methoxynicotinic acid <b>10</b>, which then undergone to chlorination <i>via</i> SOCl<sub>2</sub> to furnish 6-methoxynicotinoyl chloride <b>11</b> where the chloride was subsequently substituted with an azide functionality to produce 6-methoxynicotinoyl azide <b>12</b>. The azid derivative <b>12</b> was subjected to Curtius Rearrangement to get 5-isocyanato-2-methoxypyridine <b>13</b>, that refluxed with 5-bromoindoline-2,3-dione <b>3c</b> in dry toluene to furnish the final compound <b>14</b>.</p> <p><sup>1</sup>H NMR spectra of the final compounds <b>5aâ€"m</b> and <b>9aâ€"c</b> were confirmed with the presence of a D<sub>2</sub>O exchangeable singlet signal attributable to the proton of the hydrazide linker at <i>Î´</i> (13.31â€"13.86) ppm. Moreover, <sup>1</sup>H NMR spectra for compounds <b>9aâ€"c</b> confirmed the presence of singlet signal in the aliphatic region for the CH<sub>3</sub> group around <i>Î´</i> 2.71â€‰ppm, in addition to the extra aromatic protons for the 6-phenyl ring at a range of <i>Î´</i> 7.44â€"7.57â€‰ppm, whereas, spectra for compounds <b>5jâ€"m</b> and <b>14</b> confirmed the appearance of singlet signal for OCH<sub>3</sub> groups at <i>Î´</i> (3.82â€"3.97) ppm.</p> <p>In addition, the propyl moiety in compounds (<b>5a</b>, <b>e</b>, <b>g</b>, <b>j</b>, and <b>9a</b>) was confirmed with the appearance of two triplet signals for (â€"CH<sub>2</sub>C<u>H<sub>3</sub></u>) and (<i>N</i>-CH<sub>2</sub>) at <i>Î´</i> (0.89-0.91) and (3.70â€"3.75) ppm, respectively. Also, <sup>1</sup>H NMR spectra for compounds (<b>5b</b>, <b>f</b>, <b>h</b>, <b>k</b>, and, <b>9b</b>) displayed two doublet signals for (â€"CH(C<u>H<sub>3</sub></u>)<sub>2</sub>) and (<i>N</i>-CH<sub>2</sub>) in the isobutyl moiety at <i>Î´</i> (0.90-0.93) and (3.56-3.74) ppm, respectively, whereas, the ethyl acetate group of compounds (<b>5c</b>, <b>i</b>, <b>l</b>, and <b>9c</b>) was represented by a triplet signal for (CO-CH<sub>2</sub>C<u>H<sub>3</sub></u>), quartette signal for (COâ€"C<u>H<sub>2</sub></u>CH<sub>3</sub>) as well as singlet signal for (<i>N</i>-CH<sub>2</sub>) at <i>Î´</i> (1.20â€"1.22), (4.16â€"4.17) and (4.72â€"7.74) ppm, respectively. Furthermore, the <i>N</i>-benzyl substituted counterparts (<b>5d</b> and 5<b>m</b>) showed singlet signals around <i>Î´</i> 5.02â€‰ppm attributed to the benzylic (â€"C<u>H<sub>2</sub></u>â€"C<sub>6</sub>H<sub>5</sub>) protons.</p> <p>On the other hand, <sup>13â€‰</sup>C NMR spectra for hybrids <b>5aâ€"m</b> and <b>9aâ€"c</b> showed two signals resonating in the range <i>Î´</i> (161.20â€"161.84) and (162.90â€"166.52) ppm attributable for the carbonyl carbons of the nicotinic hydrazide and indoline-2-one moieties, respectively. Moreover, compounds <b>5c</b>, <b>l</b>, and <b>9c</b> showed an extra signal for Câ€‰=â€‰O group for the ester moiety at <i>Î´</i> 167.86â€‰ppm, whereas, compound <b>14</b> displayed the Câ€‰=â€‰O signal for urea linker at <i>Î´</i> 153.69â€‰ppm, and two signals for indoline-2,3-dione moiety at <i>Î´</i> 159.57 and 183.65â€‰ppm. Additionally, <sup>13â€‰</sup>C NMR spectra for compounds <b>9aâ€"c</b> showed a signal corresponding to CH<sub>3</sub> carbon at <i>Î´</i> 23.88â€"27.24â€‰ppm, while, spectra for compounds <b>5jâ€"m</b> and <b>14</b> displayed a signal corresponding to OCH<sub>3</sub> carbon at <i>Î´</i> (53.53â€"54.44) ppm.</p> <p>Furthermore, the carbons of the <i>N</i>-propyl group in compounds (<b>5a</b>, <b>e</b>, <b>g</b>, <b>k</b>, and <b>9a</b>) appeared as three signals resonating at <i>Î´</i> (11.60â€"11.65â€‰ppm), (20.81â€"20.87â€‰ppm), and (41.28â€"41.48â€‰ppm) for â€"CH<sub>2</sub><u>C</u>H<sub>3</sub>, <i>N</i>-CH<sub>2</sub><u>C</u>H<sub>2</sub>, and <i>N</i>-CH<sub>2</sub>, respectively, and the carbons of the <i>N</i>-isobutyl group in compounds (<b>5f</b>, <b>l</b> and <b>9b</b>) appeared as three signals at a range of <i>Î´</i> (20.36â€"20.45â€‰ppm), (27.22â€"23.88â€‰ppm) and (47.10â€"56.51â€‰ppm) due to â€"CH(<u>C</u>H<sub>3</sub>)<sub>2</sub>â€", â€"<u>C</u>H(CH<sub>3</sub>)<sub>2</sub>â€" and â€"<i>N</i>-CH<sub>2</sub>â€", respectively. Finally, a signal attributable to the benzylic (â€"CH<sub>2</sub>â€") carbon in the <i>N</i>-benzyl derivatives (<b>5d</b> and 5<b>m</b>) appeared around <i>Î´</i> 43.10â€‰ppm.</p> </div> <div class="biologicalevaluation" title="sec"><span class="label" tagx="label" title="label">2.2.</span><div class="title" tagx="title" title="title">
Biological evaluation</div> <div class="anti-tubercularactivity" title="sec"><span class="label" tagx="label" title="label">2.2.1.</span><div class="title" tagx="title" title="title">
Anti-tubercular activity</div> <p>All of the newly synthesised hybrids were evaluated for their anti-tubercular action towards <i>M. tuberculosis</i> (ATCC 27294) using the Microplate Alamar Blue Assay (MABA)<a href="#CIT0032"><sup>32</sup></a>. INH was used as the reference drug. The obtained results for the anti-mycobacterial activity were summarised in (<a href="#t0001">Table 1</a>) and expressed as a minimum inhibitory concentration (MIC).</p> <div class="table-wrap_UNKNOWN" id="t0001" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 1.</span> <p>MIC (Âµg/mL) for hybrids (<b>5aâ€"m</b>, <b>9aâ€"c</b>, and <b>14</b>) against <i>M. tuberculosis</i> (ATCC 27294) and Isoniazid/Streptomycin resistant <i>M. tuberculosis</i> (ATCC 35823), and LogP measurements for hybrids (<b>5aâ€"m</b>, <b>9aâ€"c</b>, and <b>14</b>).<span class="inline-graphic" title="inline-graphic" /></p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th align="left">Compound</th> <th align="center">X or R<sub>2</sub></th> <th align="center">R</th> <th align="center">R<sub>1</sub></th> <th align="center"><i>M. tuberculosis</i> (ATCC 27294)</th> <th align="center"><i>M. tuberculosis</i> (ATCC 35823)</th> <th align="center">LogP</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>5a</b></td> <td align="left">H</td> <td align="left">â€"CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub></td> <td align="left">Â </td> <td align="char" char=".">3.9</td> <td align="char" char=".">125</td> <td align="char" char=".">1.65</td> </tr> <tr> <td align="left"><b>5b</b></td> <td align="left">H</td> <td align="left">â€"CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td> <td align="left">Â </td> <td align="char" char=".">1.95</td> <td align="char" char=".">62.5</td> <td align="char" char=".">2.04</td> </tr> <tr> <td align="left"><b>5c</b></td> <td align="left">H</td> <td align="left">â€"CH<sub>2</sub>COOCH<sub>2</sub>CH<sub>3</sub></td> <td align="left">Â </td> <td align="char" char=".">7.81</td> <td align="char" char=".">NA</td> <td align="char" char=".">1.46</td> </tr> <tr> <td align="left"><b>5d</b></td> <td align="left">H</td> <td align="left">â€"CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub></td> <td align="left">Â </td> <td align="char" char="."><b>0.24</b></td> <td align="char" char="."><b>15.63</b></td> <td align="char" char=".">2.55</td> </tr> <tr> <td align="left"><b>5e</b></td> <td align="left">Cl</td> <td align="left">â€"CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub></td> <td align="left">Â </td> <td align="char" char=".">3.9</td> <td align="char" char=".">NA</td> <td align="char" char=".">2.2</td> </tr> <tr> <td align="left"><b>5f</b></td> <td align="left">Cl</td> <td align="left">â€"CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td> <td align="left">Â </td> <td align="char" char=".">0.48</td> <td align="char" char="."><b>15.63</b></td> <td align="char" char=".">2.6</td> </tr> <tr> <td align="left"><b>5g</b></td> <td align="left">Br</td> <td align="left">â€"CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub></td> <td align="left">Â </td> <td align="char" char="."><b>0.24</b></td> <td align="char" char="."><b>3.9</b></td> <td align="char" char=".">2.47</td> </tr> <tr> <td align="left"><b>5h</b></td> <td align="left">Br</td> <td align="left">â€"CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td> <td align="left">Â </td> <td align="char" char="."><b>0.24</b></td> <td align="char" char="."><b>3.9</b></td> <td align="char" char=".">2.87</td> </tr> <tr> <td align="left"><b>5i</b></td> <td align="left">Br</td> <td align="left">â€"CH<sub>2</sub>COOCH<sub>2</sub>CH<sub>3</sub></td> <td align="left">Â </td> <td align="char" char=".">7.81</td> <td align="char" char=".">NA</td> <td align="char" char=".">2.29</td> </tr> <tr> <td align="left"><b>5j</b></td> <td align="left">H</td> <td align="left">â€"CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub></td> <td align="left">OCH<sub>3</sub></td> <td align="char" char=".">0.98</td> <td align="char" char="."><b>15.63</b></td> <td align="char" char=".">2.24</td> </tr> <tr> <td align="left"><b>5k</b></td> <td align="left">H</td> <td align="left">â€"CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td> <td align="left">OCH<sub>3</sub></td> <td align="char" char=".">0.98</td> <td align="char" char=".">62.5</td> <td align="char" char=".">2.63</td> </tr> <tr> <td align="left"><b>5l</b></td> <td align="left">H</td> <td align="left">â€"CH<sub>2</sub>COOCH<sub>2</sub>CH<sub>3</sub></td> <td align="left">OCH<sub>3</sub></td> <td align="char" char=".">3.9</td> <td align="char" char=".">125</td> <td align="char" char=".">2.05</td> </tr> <tr> <td align="left"><b>5m</b></td> <td align="left">H</td> <td align="left">â€"CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub></td> <td align="left">OCH<sub>3</sub></td> <td align="char" char=".">7.81</td> <td align="char" char=".">NA</td> <td align="char" char=".">3.14</td> </tr> <tr> <td align="left"><b>9a</b></td> <td align="left">CH<sub>3</sub></td> <td align="left">â€"CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub></td> <td align="left">C<sub>6</sub>H<sub>5</sub></td> <td align="char" char=".">31.25</td> <td align="char" char=".">NA</td> <td align="char" char=".">4.45</td> </tr> <tr> <td align="left"><b>9b</b></td> <td align="left">CH<sub>3</sub></td> <td align="left">â€"CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td> <td align="left">C<sub>6</sub>H<sub>5</sub></td> <td align="char" char=".">15.63</td> <td align="char" char=".">NA</td> <td align="char" char=".">4.85</td> </tr> <tr> <td align="left"><b>9c</b></td> <td align="left">CH<sub>3</sub></td> <td align="left">â€"CH<sub>2</sub>COOCH<sub>2</sub>CH<sub>3</sub></td> <td align="left">C<sub>6</sub>H<sub>5</sub></td> <td align="char" char=".">15.63</td> <td align="char" char=".">NA</td> <td align="char" char=".">4.26</td> </tr> <tr> <td align="left"><b>14</b></td> <td align="left">Â </td> <td align="left">Â </td> <td align="left">Â </td> <td align="char" char=".">3.9</td> <td align="char" char=".">62.5</td> <td align="char" char=".">1.94</td> </tr> <tr> <td align="left"><b>INH</b></td> <td align="left">Â </td> <td align="left">Â </td> <td align="left">Â </td> <td align="char" char=".">0.24</td> <td align="char" char=".">&amp;gt;125</td> <td align="char" char=".">Â </td> </tr> <tr> <td align="left"><b>Streptomycin</b></td> <td align="left">Â </td> <td align="left">Â </td> <td align="left">Â </td> <td align="char" char=".">Â </td> <td align="char" char=".">&amp;gt;125</td> <td align="char" char=".">Â </td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p>NA: not determined, MIC &amp;gt;125â€‰Âµg/mL.</p> </div> <div class="fn-type-" title=""> <p>Bold values represent the best activity.</p> </div> </div> </div> <p>The results revealed that most tested compounds exerted potent to moderate anti-tubercular action with MIC range = 0.24-7.81â€‰Âµg/mL. Compounds <b>5d</b>, <b>5g</b>, and <b>5h</b> were found to be as potent as INH with MIC = 0.24â€‰Âµg/mL. Compounds <b>5f</b>, <b>5j</b>, and <b>5k</b> revealed potent activity with MIC range = 0.48â€"0.98â€‰Âµg/mL, whereas derivatives <b>5aâ€"5c</b>, <b>5e</b>, <b>5i</b>, <b>5l</b>, <b>5m</b>, and <b>14</b> exhibited a moderate activity with MIC range = 1.95â€"7.81â€‰Âµg/mL.</p> <p>Concerning the structureâ€"activity relationship, it was observed that the anti-tubercular activity of compounds <b>5aâ€"5i</b> was affected by two main factors; <i>N</i>-substitution and incorporation of halogen at position 5 of the oxindole ring. Regarding <i>N</i>-substitution it was shown that, compounds bearing isobutyl group: <b>5b</b>, <b>5f</b>, and <b>5h</b> exhibited remarkable activity with MIC values = 1.95, 0.48, and 0.24â€‰Âµg/mL, respectively. Similarly, compound <b>5d</b> with <i>N</i>-benzyl moiety revealed a potent activity with MIC = 0.24â€‰Âµg/mL. In contrast, compounds <b>5c</b> and <b>5i</b> carrying the <i>N</i>-ethylcarboxylate group were found to be the least active derivatives (MIC = 7.81â€‰Âµg/mL). Moreover, the contribution of substitution at position 5 of oxindole ring on the activity was quite important. Incorporating 5-Br group in compounds <b>5g</b> and <b>5h</b> (MIC = 0.24â€‰Âµg/mL) showed better activity than 5-Cl substituted compounds <b>5e</b> and <b>5f</b> (MIC = 0.48 and 3.9â€‰Âµg/mL, respectively) and the unsubstituted congeners <b>5aâ€"5c</b> (MIC range = 3.9â€"7.81â€‰Âµg/mL).</p> <p>Then we turned our attention to study the impact of substitution at position 6 on the nicotinohydrazide moiety of the new hybrids. Comparing the anti-tubercular activity of 6-methoxy nicotinohydrazide derivatives <b>5jâ€"5m</b> against the unsubstituted counterparts <b>5aâ€"5d</b>, it was found that the introduction of 6-methoxy group in compounds <b>5jâ€"5l</b> (MIC = 0.98-3.9â€‰Âµg/mL) enhanced the anti-tubercular activity by 2-4 fold compared to unsubstituted analogues <b>5aâ€"5c</b> (MIC range: 1.95â€"7.81â€‰Âµg/mL) except for the benzyl derivatives <b>5d</b> and <b>5m</b>. Conversely, the introduction of 6-phenyl moiety to the nicotinohydrazide moiety as in compounds <b>9aâ€"c</b> (MIC = 15.63â€"31.25â€‰Âµg/mL) led to a reduced anti-tubercular activity that may be due to steric factors.</p> <p>In conclusion, increasing the lipophilicity of the isatin scaffold via C-5 substitution with halogens (Brâ€‰&amp;gt;â€‰Cl) was more advantageous for activity. Also, the anti-mycobacterial action of the target hybrids was decreased in the following order; 6-methoxy nicotinohydrazideâ€‰&amp;gt;â€‰unsubstituted nicotinohydrazide &amp;gt; 2-methyl-6-phenyl nicotinohydrazide (<a href="#F0003">Figure 3</a>).</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 3.</span></a></div>   <p>Summary for the structure activity relationships for anti-mycobacterial activity of the target hybrids.</p>   </div> </div> <div class="anti-tubercularactivitytowardsisoniazidandstreptomycinresistantm.tuberculosis(atcc35823)" title="sec"><span class="label" tagx="label" title="label">2.2.2.</span><div class="title" tagx="title" title="title">
Anti-tubercular activity towards Isoniazid and Streptomycin resistant M. tuberculosis (ATCC 35823)</div> <p>The anti-tubercular activity against Isoniazid and Streptomycin resistant <i>M. tuberculosis</i> (ATCC 35823) was evaluated using MABA<a href="#CIT0032"><sup>32</sup></a>. Investigating the results of the target compounds <b>5aâ€"m</b>, <b>9aâ€"c</b>, and <b>14</b> (<a href="#t0001">Table 1</a>), it was found that many of the tested derivatives exhibited potent to moderate activity with MIC range = 3.9-62.5â€‰Âµg/mL. Compounds <b>5g</b> and <b>5h</b> with the best anti-tubercular effect against <i>M. tuberculosis</i> (ATCC 27294), showed excellent activity (MIC = 3.9â€‰Âµg/mL) resistant <i>M. tuberculosis</i> strain (ATCC 35823), with more than 32 fold increase in the activity compared to INH and Streptomycin (MIC &amp;gt; 125â€‰Âµg/mL). Moreover, compounds <b>5d</b>, <b>5f</b> and <b>5j</b> elicited a good activity with MIC = 15.63â€‰Âµg/mL, whereas derivatives <b>5b</b>, <b>5k</b>, and <b>14</b> produced a moderate activity with MIC = 62.5â€‰Âµg/mL. Finally, compounds <b>5a</b> and <b>5l</b> were found to be least active showing MIC value = 125â€‰Âµg/mL, while the 6-phenyl pyridine derivatives <b>9aâ€"c</b> were inactive with MIC &amp;gt;125â€‰Âµg/mL.</p> </div> <div class="antibacterialactivityagainstbronchitiscausing-bacteria" title="sec"><span class="label" tagx="label" title="label">2.2.3.</span><div class="title" tagx="title" title="title">
Antibacterial activity against bronchitis causing-bacteria</div> <p>The antibacterial activity for the synthesised compounds <b>5aâ€"m</b>, <b>9aâ€"c</b>, and <b>14</b> was evaluated against bronchitis causing-bacteria; Gram-negative <i>Mycoplasma pneumoniae</i> (ATCC 15531), <i>K. pneumoniae</i> (ATCC 43816), <i>H. influenzae</i> (ATCC 10211), <i>M. catarrhalis</i> (ATCC 25238), <i>B. pertussis</i> (ATCC 9340) and Gram-positive <i>S. pneumoniae</i> (ATCC 1659) using XTT Susceptibility Assay (<a href="#t0002">Table 2</a>)<a href="#CIT0033"><sup>33</sup></a><sup>,</sup><a href="#CIT0034"><sup>34</sup></a>. The results showed that, most of the evaluated compounds produced a significant antibacterial activity in comparison to the reference drug Azithromycin against the tested bacterial strains. The most sensitive strain towards the new hybrids was <i>K. pneumoniae</i> (ATCC 43816) with MIC range = 0.49â€"7.81â€‰Âµg/mL, while <i>M. pneumoniae</i> (ATCC 15531) and <i>M. catarrhalis</i> (ATCC 25238) were the least sensitive strains MIC range = 0.98â€"125â€‰Âµg/mL and MIC range = 3.9 to &amp;gt;125â€‰Âµg/mL, respectively.</p> <div class="table-wrap_UNKNOWN" id="t0002" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 2.</span> <p>MIC (Âµg/mL) for hybrids (<b>5aâ€"m</b>, <b>9aâ€"c</b>, and <b>14)</b> against bronchitis causing-bacteria as determined using XTT assay.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th align="left">Compound</th> <th align="center"><i>M. pneumoniae</i> (ATCC 15531)</th> <th align="center"><i>H. influenzae</i> (ATCC 10211)</th> <th align="center"><i>S. pneumoniae</i> (ATCC 1659)</th> <th align="center"><i>K. pneumoniae</i> (ATCC 43816)</th> <th align="center"><i>M. catarrhalis</i> (ATCC 25238)</th> <th align="center"><i>B. pertussis</i> (ATCC 9340)</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>5a</b></td> <td align="char" char=".">7.81</td> <td align="char" char=".">7.81</td> <td align="char" char=".">1.95</td> <td align="char" char="."><b>0.49</b></td> <td align="char" char=".">31.25</td> <td align="char" char=".">3.9</td> </tr> <tr> <td align="left"><b>5b</b></td> <td align="char" char=".">1.95</td> <td align="char" char="."><b>0.98</b></td> <td align="char" char=".">1.95</td> <td align="char" char="."><b>0.49</b></td> <td align="char" char=".">7.81</td> <td align="char" char=".">1.95</td> </tr> <tr> <td align="left"><b>5c</b></td> <td align="char" char=".">31.25</td> <td align="char" char=".">7.81</td> <td align="char" char=".">3.9</td> <td align="char" char=".">1.95</td> <td align="char" char=".">NA</td> <td align="char" char=".">7.81</td> </tr> <tr> <td align="left"><b>5d</b></td> <td align="char" char=".">3.9</td> <td align="char" char=".">0.98</td> <td align="char" char=".">1.95</td> <td align="char" char="."><b>0.49</b></td> <td align="char" char="."><b>7.81</b></td> <td align="char" char=".">1.95</td> </tr> <tr> <td align="left"><b>5e</b></td> <td align="char" char=".">7.81</td> <td align="char" char=".">7.81</td> <td align="char" char=".">1.95</td> <td align="char" char=".">0.98</td> <td align="char" char=".">15.63</td> <td align="char" char=".">7.81</td> </tr> <tr> <td align="left"><b>5f</b></td> <td align="char" char=".">3.9</td> <td align="char" char="."><b>1.95</b></td> <td align="char" char=".">1.95</td> <td align="char" char="."><b>0.49</b></td> <td align="char" char="."><b>3.9</b></td> <td align="char" char="."><b>1.95</b></td> </tr> <tr> <td align="left"><b>5g</b></td> <td align="char" char="."><b>1.95</b></td> <td align="char" char="."><b>0.98</b></td> <td align="char" char=".">1.95</td> <td align="char" char="."><b>0.24</b></td> <td align="char" char="."><b>3.9</b></td> <td align="char" char="."><b>1.95</b></td> </tr> <tr> <td align="left"><b>5h</b></td> <td align="char" char="."><b>1.95</b></td> <td align="char" char="."><b>0.98</b></td> <td align="char" char=".">1.95</td> <td align="char" char="."><b>0.49</b></td> <td align="char" char="."><b>3.9</b></td> <td align="char" char="."><b>1.95</b></td> </tr> <tr> <td align="left"><b>5i</b></td> <td align="char" char=".">15.63</td> <td align="char" char=".">7.81</td> <td align="char" char=".">1.95</td> <td align="char" char=".">0.98</td> <td align="char" char=".">NA</td> <td align="char" char=".">7.81</td> </tr> <tr> <td align="left"><b>5j</b></td> <td align="char" char=".">3.9</td> <td align="char" char=".">3.9</td> <td align="char" char=".">1.95</td> <td align="char" char="."><b>0.49</b></td> <td align="char" char="."><b>7.81</b></td> <td align="char" char="."><b>3.9</b></td> </tr> <tr> <td align="left"><b>5k</b></td> <td align="char" char="."><b>0.98</b></td> <td align="char" char="."><b>0.98</b></td> <td align="char" char=".">1.95</td> <td align="char" char="."><b>0.49</b></td> <td align="char" char=".">3.9</td> <td align="char" char="."><b>1.95</b></td> </tr> <tr> <td align="left"><b>5l</b></td> <td align="char" char=".">7.81</td> <td align="char" char=".">15.63</td> <td align="char" char=".">1.95</td> <td align="char" char=".">0.98</td> <td align="char" char=".">15.63</td> <td align="char" char=".">15.63</td> </tr> <tr> <td align="left"><b>5m</b></td> <td align="char" char=".">62.5</td> <td align="char" char=".">7.81</td> <td align="char" char=".">7.81</td> <td align="char" char=".">1.95</td> <td align="char" char=".">NA</td> <td align="char" char=".">7.81</td> </tr> <tr> <td align="left"><b>9a</b></td> <td align="char" char=".">125</td> <td align="char" char=".">31.25</td> <td align="char" char=".">7.81</td> <td align="char" char=".">7.81</td> <td align="char" char=".">NA</td> <td align="char" char=".">15.63</td> </tr> <tr> <td align="left"><b>9b</b></td> <td align="char" char=".">125</td> <td align="char" char=".">62.5</td> <td align="char" char=".">15.63</td> <td align="char" char=".">7.81</td> <td align="char" char=".">NA</td> <td align="char" char=".">31.25</td> </tr> <tr> <td align="left"><b>9c</b></td> <td align="char" char=".">125</td> <td align="char" char=".">15.63</td> <td align="char" char=".">15.63</td> <td align="char" char=".">3.9</td> <td align="char" char=".">NA</td> <td align="char" char=".">7.81</td> </tr> <tr> <td align="left"><b>14</b></td> <td align="char" char=".">3.9</td> <td align="char" char="."><b>1.95</b></td> <td align="char" char=".">1.95</td> <td align="char" char="."><b>0.49</b></td> <td align="char" char=".">15.63</td> <td align="char" char="."><b>1.95</b></td> </tr> <tr> <td align="left"><b>Azith.</b></td> <td align="char" char=".">1.95</td> <td align="char" char=".">3.9</td> <td align="char" char=".">0.98</td> <td align="char" char=".">0.49</td> <td align="char" char=".">7.81</td> <td align="char" char=".">3.9</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p>NA: not determined.</p> </div> <div class="fn-type-" title=""> <p>Bold values represent the best activity.</p> </div> </div> </div> <p>Interestingly, compounds <b>5g</b> and <b>5h</b> showing best anti-tubercular activity with the minimal bacterial resistance against resistant-TB, revealed a broad-spectrum antibacterial action against most of the tested bronchitis causing-bacteria. They were found to be more potent than the reference drug against <i>H. influenzae</i>, <i>M. catarrhalis</i>, and <i>B</i>. <i>pertussis</i> (MIC = 0.24â€"3.9â€‰Âµg/mL, Azithromycin MIC = 3.9â€"7.81â€‰Âµg/mL). Additionally, they were equipotent to Azithromycin against <i>M. pneumoniae, S. pneumoniae</i> and <i>K. pneumoniae</i> (MIC = 1.95, 0.98, and 0.49â€‰Âµg/mL, respectively).</p> <p>Moreover, compound <b>5k</b> showed MIC values (0.98-3.9â€‰Âµg/mL) less than that expressed by Azithromycin (MIC = 1.95â€"7.81â€‰Âµg/mL) against four bacterial strains: <i>M. pneumoniae</i> (ATCC 15531), <i>H. influenza</i>, <i>M. catarrhalis</i> (ATCC 25238) and <i>B. pertussis</i> (ATCC 9340). Also, compound <b>5j</b> was as potent as the reference drug against <i>H. influenzae, K. pneumoniae</i> (ATCC 43816), <i>M. catarrhalis</i> (ATCC 25238), and <i>B. pertussis</i> (ATCC 9340). Furthermore, compounds <b>5f</b> and <b>14</b> were two-fold more potent (with MIC = 1.95â€‰Âµg/mL) than Azithromycin (MIC = 3.9â€‰Âµg/mL) against <i>H. influenza</i> (ATCC 10211) and <i>B. pertussis</i> (ATCC 9340) and equipotent to Azithromycin against <i>K. pneumoniae</i> (ATCC 43816) with MIC = 0.49â€‰Âµg/mL. Finally, derivatives <b>5a</b>, <b>5b</b>, and <b>5d</b> produced the same MIC values = 0.49â€‰Âµg/mL as that expressed by the standard drug against <i>K. pneumoniae</i> (ATCC 43816).</p> </div> <div class="cytotoxicityagainstnon-tumorigeniclungfibroblastwi-38cells" title="sec"><span class="label" tagx="label" title="label">2.2.4.</span><div class="title" tagx="title" title="title">
Cytotoxicity against non-tumorigenic lung fibroblast WI-38 cells</div> <p>In order to assess the cytotoxic impact of hybrids <b>5g</b> and <b>5h</b> on normal human cells, an MTT cytotoxicity assay was carried out against non-tumorigenic WI-38 cells. The obtained results ascribed to hybrids <b>5g</b> and <b>5h</b> non-significant cytotoxic action with IC<sub>50</sub> value = 60.95 and 54.01, respectively (<a href="#t0003">Table 3</a>), thus providing favourable selectivity indices (SI) equal to 15.6 and 13.8, respectively.</p> <div class="table-wrap_UNKNOWN" id="t0003" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 3.</span> <p><i>In vitro</i> cytotoxic effect for hybrids <b>5g</b> and <b>5h</b> towards non-tumorigenic WI-38 cells, and their Selectivity index (S.I.).</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th align="left">Compound</th> <th align="center">IC<sub>50 <br /><br /></sub>WI-38 cells (Âµg/mL)</th> <th align="center">MIC <br /><br />Resistant TB (Âµg/mL)</th> <th align="center">Selectivity Index</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>5g</b></td> <td align="center">60.95â€‰Â±â€‰3.17</td> <td align="center">3.9</td> <td align="center">15.6</td> </tr> <tr> <td align="left"><b>5h</b></td> <td align="center">54.01â€‰Â±â€‰2.69</td> <td align="center">3.9</td> <td align="center">13.8</td> </tr> </tbody> </table> </div> </div> </div> </div> <div class="moleculardocking" title="sec"><span class="label" tagx="label" title="label">3.</span><div class="title" tagx="title" title="title">
Molecular docking</div> <p>Over the past decade, several druggable targets have been utilised in TB-drug discovery to develop new therapies in order to fight the global epidemic of TB. Most of these enzyme targets have an essential role in energy production, cell wall biosynthesis, and DNA replication, repair, and transcription. Examples of these enzymes are; Alanine racemase (Alr), Maltosyltransferase (GlgE), <i>N</i>-Acetylglucosamine-1-phosphate uridyltransferase (GlmU), Pantothenate synthetase (PS), Mtb ATP synthase subunit C (AtpE), Flavin-dependent thymidylate synthase (TS or ThyA), and flavoenzyme Decaprenylphosphoryl-<i>Î²</i>-D-Ribose 2â€²-Epimerase (DprE1)<a href="#CIT0030"><sup>30</sup></a>.</p> <p>On account of their superior anti-mycobacterial activity, compounds <b>5g</b> and <b>5h</b> were selected for further <i>in silico</i> investigation to explore their possible molecular target. Two promising drug enzymes in <i>M. tuberculosis</i> were suggested as potential targets for the target compounds in this study; the flavoenzyme Decaprenylphosphoryl-<i>Î²</i>-D-Ribose 2â€²-Epimerase (DprE1) and the enoyl-acyl carrier protein reductase (InhA) enzymes. Both enzymes play an essential role in the metabolism of the cell wall and the synthesis of mycolic acid, respectively<a href="#CIT0030"><sup>30</sup></a><sup>,</sup><a href="#CIT0031"><sup>31</sup></a>. The selection of these two enzymes is based on a pilot docking study that explored the plausible binding interactions and energy scores for the prepared compounds with different enzyme targets.</p> <p>The crystal structures of the two enzymes were downloaded from the protein data bank PDB ID: 4NCR for DprE1 and 2B35 for InhA. Despite, the importance of docking in providing a predicated binding mode and an account for a ligand strength, it remains a theoretical technique that needs proper validation by comparison with an experimental reference. Therefore, both co-crystallised ligands were re-docked into their corresponding enzymes. The calculated RMSD values between the co-crystallised and docked pose were 0.52 and 0.71 for DprE1 and InhA, orderly which indicates a valid and reliable docking protocol. Compound <b>5h</b> has achieved âˆ’10.1 and âˆ’7.9â€‰kcal/mole energy score for DprE1 and InhA, respectively, whereas, compound <b>5g</b> has achieved âˆ’9.7 and âˆ’7.3â€‰kcal/mole for DprE1 and InhA, respectively. Interestingly, both compounds <b>5g</b> and <b>5h</b> achieved a higher energy score than the co-crystalized ligand (âˆ’9.3â€‰kcal/mole) in DprE1. These findings suggested that DprE1 may be a plausible target for the herein reported compounds.</p> <p>Inspection of the docking poses for the two examined compounds revealed their ability to fit perfectly in the active site of the DprE1 enzyme establishing different types of interactions (<a href="#F0004">Figures 4</a> and <a href="#F0005">5</a>). The oxindole ring in both compounds <b>5g</b> and <b>5h</b> was engaged in two H-bond interactions <i>via</i> its carbonyl oxygen (Câ€‰=â€‰O) functionality with His-132 and Tyr-415 amino acids. Furthermore, the NH of the hydrazide linker and the nitrogen atom of the pyridine ring were involved in H-bond interactions with His-132 and Asn-385, respectively. Moreover, the nitrogen atom of the pyridine ring in compound <b>5h</b> achieved an extra hydrogen bond interaction with Cys-387 which may explain its higher energy score than <b>5g</b>. Worthy of note, the <i>N</i>-isobutyl group of compound <b>5h</b> established several hydrophobic interactions with non-polar residues lining a hydrophobic pocket, such as Pro-116, Val-121, Ile-131, and Ala-417.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 4.</span></a></div>   <p>The 2D diagram and 3D representation for compound <b>5g</b> displaying its interactions with the DprE1 binding site.</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 5.</span></a></div>   <p>The 2D diagram and 3D representation for compound <b>5h</b> displaying its interactions with the DprE1 binding site.</p>   </div> <p>The 2â€‰D diagrams for interactions of compounds <b>5g</b> and <b>5h</b> in InhA active site (<a href="https://doi.org/10.1080/14756366.2020.1868450">Figure S1</a>), and the 3â€‰D illustrations of the superimposition for the docking poses and the co-crystalized ligands in DprE1 and InhA active sites (<a href="https://doi.org/10.1080/14756366.2020.1868450">Figure S2</a>), as well as the detailed interactions achieved by compounds <b>5g</b> and <b>5h</b> within the DprE1 binding site (<a href="https://doi.org/10.1080/14756366.2020.1868450">Table S3</a>) were provided in the Supporting Materials.</p> </div> <div class="conclusions" title="conclusions"><span class="label" tagx="label" title="label">4.</span><div class="title" tagx="title" title="title">
Conclusion</div> <p>In this work, different sets of isatin-nicotinohydrazide hybrids (<b>5aâ€"m</b>, <b>9aâ€"c</b>) and isatin-3-pyridylamine hybrid <b>14</b> were designed and synthesised. The anti-mycobacterial activity towards <i>M. tuberculosis</i> (ATCC 27294), as well as towards the INH and Streptomycin resistant <i>M. tuberculosis</i> (ATCC 35823), were evaluated for the seventeen newly synthesised 2-oxindolin-3-ylidene-nicotinohydrazide derivatives. The obtained results identified compounds <b>5g</b> and <b>5h</b> as the most potent anti-tubercular agents in this study (MIC = 0.24â€‰Âµg/mL), with minimal mycobacterial resistance (MIC = 3.9â€‰Âµg/mL). Furthermore, all herein reported hybrids were examined for their antibacterial activity against six bronchitis causing-bacteria; <i>M. pneumoniae</i>, <i>H. influenzae</i>, <i>K. pneumoniae</i>, <i>M. catarrhalis</i>, <i>B. pertussis</i>, and <i>S. pneumonia</i>. Most hybrids exerted significant antibacterial activity in comparison to the reference drug Azithromycin against the tested bacterial strains. The most sensitive strain was <i>K. pneumoniae</i> with MIC range = 0.49â€"7.81â€‰Âµg/mL. Interestingly, compounds <b>5g</b> and <b>5h</b> displayed a broad-spectrum antibacterial activity against most of the tested bronchitis causing-bacteria. Moreover, an <i>in silico</i> molecular modelling study has proposed DprE1 as a potential enzyme target for herein reported isatin-nicotinohydrazide hybrids. Compounds <b>5g</b> and <b>5h</b> were able to fit perfectly in the active site of the DprE1 enzyme achieving a higher energy score (âˆ’9.7 and âˆ’10.1â€‰kcal/mole, respectively) than the co-crystalized ligand (âˆ’9.3â€‰kcal/mole). The oxindole ring was engaged in two H-bond interactions via its carbonyl oxygen (Câ€‰=â€‰O) functionality with His-132 and Tyr-415 amino acids, whereas, the NH of the hydrazide linker and the nitrogen atom of the pyridine ring were involved in H-bond interactions with His-132 and Asn-385, respectively. In addition, the <i>N</i>-isobutyl group of compound <b>5h</b> established several hydrophobic interactions with non-polar residues lining a hydrophobic pocket.</p> </div> <div class="experimental" title="sec"><span class="label" tagx="label" title="label">5.</span><div class="title" tagx="title" title="title">
Experimental</div> <div class="chemistry" title="sec"><span class="label" tagx="label" title="label">5.1.</span><div class="title" tagx="title" title="title">
Chemistry</div> <div class="general" title="sec"><span class="label" tagx="label" title="label">5.1.1.</span><div class="title" tagx="title" title="title">
General</div> <p>I.R. spectra have been recorded on Schimadzu FT-IR 8400S spectrophotometer. NMR spectra were recorded by Bruker-Avance 400 spectrometer. <sup>13â€‰</sup>C NMR spectra were run at 100â€‰MHz in deuterated dimethylsulphoxide (DMSO-d<sub>6</sub>). Chemical shifts (<i>Î´<sub>H</sub></i>) are reported relative to the solvent (DMSO-d<sub>6</sub><i>)</i>. NMR analyses were carried out at the NMR Unit, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt, whereas IR analyses were carried out at the Faculty of Science, Mansoura University, Mansoura, Egypt. Elemental analyses were carried out at the Regional Centre for Microbiology and Biotechnology, Al-Azhar University, Cairo, Egypt. Compounds <b>2a</b>,<b>b</b><a href="#CIT0035"><sup>35</sup></a>, <b>4aâ€"i</b><a href="#CIT0036"><sup>36</sup></a><sup>,</sup><a href="#CIT0037"><sup>37</sup></a>, <b>8</b><a href="#CIT0038"><sup>38</sup></a>, and <b>11</b><a href="#CIT0039"><sup>39</sup></a>, were prepared as described previously.</p> </div> <div class="synthesisoftargetcompounds5aâ€" title="sec"><span class="label" tagx="label" title="label">5.1.2.</span><div class="title" tagx="title" title="title">
Synthesis of target compounds 5aâ€"m and 9aâ€"c</div> <p>In a round-bottom flask, the appropriate nicotinohydrazide derivative <b>2aâ€"b</b> or <b>8</b> (2.5â€‰mmol) were added to an equivalent amount of <i>N</i>-substituted indoline-2,3-dione derivatives <b>4aâ€"i</b> in 15â€‰ml of glacial acetic acid. The previous mixture was heated under reflux with TLC monitoring, after complete consummation of starting materials, the reaction flask was cooled to room temperature. The formed precipitate was collected under vacuum, washed with hexane, cold water and recrystallized from dioxane/methanol mixture to furnish final compounds <b>5aâ€"m</b> and <b>9aâ€"c</b>, respectively.</p> </div> <div class="synthesisoftargetcompound14" title="sec"><span class="label" tagx="label" title="label">5.1.3.</span><div class="title" tagx="title" title="title">
Synthesis of target compound 14</div> <p>6-Methoxynicotinoyl azide <b>12</b> (0.3â€‰g, 1.6â€‰mmol) was dissolved in anhydrous toluene (20â€‰ml) which then heated under reflux for 1â€‰h. To the previous solution, an equivalent amount of 5-bromoisatin was added and the reaction mixture was refluxed for 5â€‰h. The produced precipitate was filtrated while hot washed with hexane and recrystallized from acetonitrile to furnish compound <b>14</b>.</p> <p>Full characterisation details (NMR, IR, and elemental analysis) for the target hybrids (<b>5aâ€"m</b>, <b>9aâ€"c</b>, and <b>14</b>) have been provided in the Supporting Materials.</p> </div> </div> <div class="biologicalevaluation" title="sec"><span class="label" tagx="label" title="label">5.2.</span><div class="title" tagx="title" title="title">
Biological evaluation</div> <div class="anti-tubercularactivity" title="sec"><span class="label" tagx="label" title="label">5.2.1.</span><div class="title" tagx="title" title="title">
Anti-tubercular activity</div> <p>Microplate Alamar blue assay (MABA)<a href="#CIT0032"><sup>32</sup></a> has been utilised to determine MICs for all herein prepared hybrids (<b>5aâ€"m</b>, <b>9aâ€"c</b>, and <b>14</b>) against M. tuberculosis ATCC 27294 (Isoniazid-susceptible strain) and <i>Mycobacterium tuberculosis</i> ATCC 35823 (Isoniazid and Streptomycin resistant strain). The detailed procedures were presented in the supporting materials.</p> </div> <div class="xttsusceptibilityassayfortheantibacterialactivity" title="sec"><span class="label" tagx="label" title="label">5.2.2.</span><div class="title" tagx="title" title="title">
XTT Susceptibility Assay for the antibacterial activity</div> <p>A colorimetric broth microdilution method was utilised to determine the MIC for the tested hybrids following the XTT [2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide]-reduction assay<a href="#CIT0033"><sup>33</sup></a><sup>,</sup><a href="#CIT0034"><sup>34</sup></a>. MICs for the tested hybrids was assessed against bacteria causing bronchitis; Gram-negative bacteria: <i>H. influenzae ATCC 10211</i>, <i>M. pneumoniae ATCC 15531</i>, <i>K. pneumoniae ATCC 43816, M. catarrhalis ATCC 25238</i>, and <i>Bordetella pertussis ATCC 9340</i>, as well as <i>S. pneumoniae ATCC 1659</i>, representing Gram-positive bacterium, that obtained from the American type culture collection. The detailed experimental procedures have been added in the supporting materials.</p> </div> <div class="cytotoxicityassay" title="sec"><span class="label" tagx="label" title="label">5.2.3.</span><div class="title" tagx="title" title="title">
Cytotoxicity assay</div> <p>The MTT assay<a href="#CIT0040"><sup>40</sup></a> was used to assess the cytotoxic impact of hybrids <b>5g</b> and <b>5h</b> towards the normal human lung WI-38 cells as reported earlier<a href="#CIT0041"><sup>41</sup></a>.</p> </div> </div> <div class="moleculardocking" title="sec"><span class="label" tagx="label" title="label">5.3.</span><div class="title" tagx="title" title="title">
Molecular docking</div> <p>Aiming to define the molecular target for the best two lead compounds, the crystal structures of both DprE1 and InhA enzymes of TB were downloaded from the Protein data bank ID: 4NCR and 2B35, respectively<a href="#CIT0042"><sup>42</sup></a><sup>,</sup><a href="#CIT0043"><sup>43</sup></a>. Vina Autodock software was implemented in the current work to conduct the docking studies. The program demands both the ligand and the receptor in the pdbqt format, for that, M.G.L tools were used to prepare the two enzymes and the ligands into the right format<a href="#CIT0044"><sup>44</sup></a>. Also, the active sites were determined by generating a grid box sized 24â€‰Ã—â€‰24â€‰Ã—â€‰24â€‰Ã… surrounding the binding domain of each co-crystallised ligand with its corresponding enzyme (centre_xâ€‰=â€‰17.3, centre_y = âˆ’20 and centre_zâ€‰=â€‰3.4 for 4ncr and centre_xâ€‰=â€‰17, centre_yâ€‰=â€‰12.5 and centre_zâ€‰=â€‰10.5 for 2b35). Docking validity and reliability were ensured by re-docking each co-crystallised ligands with their corresponding enzyme, then calculating the RMSD between the co-crystallised pose and the docked pose. Discovery studio 4.5 visualiser was employed in the analysis of docking results as well as in the evaluation of best candidates based on binding affinity score and interaction with receptor<a href="#CIT0045"><sup>45</sup></a>.</p> </div> </div> <div class="supplementary-material" title="supplementary-material"> <div class="title" tagx="title" title="title">
Supplementary Material</div> <div class="local-data" title="local-data">  <div class="title" tagx="title" title="title">
Supplemental Material</div>  <div class="media" title="media"><a href="IENZ_A_1868450_SM7310.pdf">LINK</a> <p>Click here for additional data file.</p>  </div> </div> </div> </div> <div class="back" title="back"> <div class="ack" title="ack"> <div class="title" tagx="title" title="title">
Acknowledgement</div> <p>This research was funded by the Deanship of Scientific Research at Princess Nourah bint Abdulrahman University through the Fast-track Research Funding Program.</p> </div> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="CIT0001" /><span class="label" tagx="label" title="label">1</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="collab'">collab: World Health Organization</span></span><span class="source" tagx="source" title="source">Global Tuberculosis Report, WHO</span>. <span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">Geneva, Switzerland</span>: <span class="publisher-name" tagx="publisher-name" title="publisher-name">WHO</span>; <span class="year" tagx="year" title="year">2019</span>.</span></li> <li tag="ref"><a name="CIT0002" /><span class="label" tagx="label" title="label">2</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="collab'">collab: World Health Organization</span></span><span class="source" tagx="source" title="source">Global Tuberculosis Report, WHO</span>. <span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">Geneva, Switzerland</span>: <span class="publisher-name" tagx="publisher-name" title="publisher-name">WHO</span>; <span class="year" tagx="year" title="year">2018</span>.</span></li> <li tag="ref"><a name="CIT0003" /><span class="label" tagx="label" title="label">3</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Coninx</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mathieu</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Debacker</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">First-line tuberculosis therapy and drug-resistant <i>Mycobacterium tuberculosis</i> in prisons</span>. <span class="source" tagx="source" title="source">Lancet</span><span class="year" tagx="year" title="year">1999</span>;<span class="volume" tagx="volume" title="volume">353</span>:<span class="fpage" tagx="fpage" title="fpage">969</span>â€"<span class="lpage" tagx="lpage" title="lpage">73</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10459906">10459906</a></span></span></li> <li tag="ref"><a name="CIT0004" /><span class="label" tagx="label" title="label">4</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Langbang</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Deka</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rahman</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kalita</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A study on bacterial pathogens causing secondary infections in patients suffering from tuberculosis and their pattern of antibiotic sensitivity</span>. <span class="source" tagx="source" title="source">Int J Curr Microbiol App Sci</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">5</span>:<span class="fpage" tagx="fpage" title="fpage">197</span>â€"<span class="lpage" tagx="lpage" title="lpage">203</span>.</span></li> <li tag="ref"><a name="CIT0005" /><span class="label" tagx="label" title="label">5</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wei</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhao</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Qian</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Pneumonia caused by <i>Mycobacterium tuberculosis</i></span>. <span class="source" tagx="source" title="source">Microb Infect</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">22</span>:<span class="fpage" tagx="fpage" title="fpage">278</span>â€"<span class="lpage" tagx="lpage" title="lpage">84</span>.</span></li> <li tag="ref"><a name="CIT0006" /><span class="label" tagx="label" title="label">6</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Arora</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Krishnaswamy</span><span class="given-names" tagx="given-names" title="given-names">UM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Moideen</span><span class="given-names" tagx="given-names" title="given-names">RP</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Padmaja</span><span class="given-names" tagx="given-names" title="given-names">MS.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Tubercular and bacterial coinfection: a case series</span>. <span class="source" tagx="source" title="source">Lung India</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">32</span>:<span class="fpage" tagx="fpage" title="fpage">172</span>â€"<span class="lpage" tagx="lpage" title="lpage">5</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25814806">25814806</a></span></span></li> <li tag="ref"><a name="CIT0007" /><span class="label" tagx="label" title="label">7</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Byrne</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Marais</span><span class="given-names" tagx="given-names" title="given-names">BJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mitnick</span><span class="given-names" tagx="given-names" title="given-names">CD</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Chronic airflow obstruction after successful treatment of multidrug-resistant tuberculosis</span>. <span class="source" tagx="source" title="source">ERJ Open Res</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">3</span>:<span class="fpage" tagx="fpage" title="fpage">00026</span>.</span></li> <li tag="ref"><a name="CIT0008" /><span class="label" tagx="label" title="label">8</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kunal</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shah</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The concomitant occurrence of pulmonary tuberculosis with bronchial anthracofibrosis</span>. <span class="source" tagx="source" title="source">Indian J Tuberc</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">64</span>:<span class="fpage" tagx="fpage" title="fpage">5</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28166918">28166918</a></span></span></li> <li tag="ref"><a name="CIT0009" /><span class="label" tagx="label" title="label">9</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kidwai</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jahan</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mishra</span><span class="given-names" tagx="given-names" title="given-names">NK.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Isatins: a diversity orientated biological profile</span>. <span class="source" tagx="source" title="source">Med Chem</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">4</span>:<span class="fpage" tagx="fpage" title="fpage">451</span>â€"<span class="lpage" tagx="lpage" title="lpage">68</span>.</span></li> <li tag="ref"><a name="CIT0010" /><span class="label" tagx="label" title="label">10</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Singh</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fong</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and preliminary antimicrobial analysis of isatin-ferrocene and isatin-ferrocenyl chalcone conjugates</span>. <span class="source" tagx="source" title="source">ACS Omega</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">3</span>:<span class="fpage" tagx="fpage" title="fpage">5808</span>â€"<span class="lpage" tagx="lpage" title="lpage">13</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30023926">30023926</a></span></span></li> <li tag="ref"><a name="CIT0011" /><span class="label" tagx="label" title="label">11</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Medvedev</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Buneeva</span><span class="given-names" tagx="given-names" title="given-names">O</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Glover</span><span class="given-names" tagx="given-names" title="given-names">V</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Biological targets for isatin and its analogues: implications for therapy</span>. <span class="source" tagx="source" title="source">Biol: Targets Ther</span><span class="year" tagx="year" title="year">2007</span>;<span class="volume" tagx="volume" title="volume">1</span>:<span class="fpage" tagx="fpage" title="fpage">151</span>â€"<span class="lpage" tagx="lpage" title="lpage">62</span>.</span></li> <li tag="ref"><a name="CIT0012" /><span class="label" tagx="label" title="label">12</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rane</span><span class="given-names" tagx="given-names" title="given-names">RA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karunanidhi</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jain</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">A recent perspective on discovery and development of diverse therapeutic agents inspired from isatin alkaloids</span>. <span class="source" tagx="source" title="source">Curr Top Med Chem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">16</span>:<span class="fpage" tagx="fpage" title="fpage">1262</span>â€"<span class="lpage" tagx="lpage" title="lpage">89</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26369813">26369813</a></span></span></li> <li tag="ref"><a name="CIT0013" /><span class="label" tagx="label" title="label">13</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pandeya</span><span class="given-names" tagx="given-names" title="given-names">SN</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Smitha</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jyoti</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sridhar</span><span class="given-names" tagx="given-names" title="given-names">SK.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Biological activities of isatin and its derivatives</span>. <span class="source" tagx="source" title="source">Acta Pharm</span><span class="year" tagx="year" title="year">2005</span>;<span class="volume" tagx="volume" title="volume">55</span>:<span class="fpage" tagx="fpage" title="fpage">27</span>â€"<span class="lpage" tagx="lpage" title="lpage">46</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15907222">15907222</a></span></span></li> <li tag="ref"><a name="CIT0014" /><span class="label" tagx="label" title="label">14</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tehrani</span><span class="given-names" tagx="given-names" title="given-names">KHME</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hashemi</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hassan</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and antibacterial activity of Schiff bases of 5-substituted isatins</span>. <span class="source" tagx="source" title="source">Chin Chem Lett</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">27</span>:<span class="fpage" tagx="fpage" title="fpage">221</span>â€"<span class="lpage" tagx="lpage" title="lpage">5</span>.</span></li> <li tag="ref"><a name="CIT0015" /><span class="label" tagx="label" title="label">15</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guo</span><span class="given-names" tagx="given-names" title="given-names">H.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Isatin derivatives and their anti-bacterial activities</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">164</span>:<span class="fpage" tagx="fpage" title="fpage">678</span>â€"<span class="lpage" tagx="lpage" title="lpage">88</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30654239">30654239</a></span></span></li> <li tag="ref"><a name="CIT0016" /><span class="label" tagx="label" title="label">16</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Thanh</span><span class="given-names" tagx="given-names" title="given-names">ND</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Giang</span><span class="given-names" tagx="given-names" title="given-names">NTK</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Quyen</span><span class="given-names" tagx="given-names" title="given-names">TH</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and evaluation of inÂ vivo antioxidant, inÂ vitro antibacterial, MRSA and antifungal activity of novel substituted isatin N-(2,3,4,6-tetra-O-acetyl-Î²-d-glucopyranosyl)thiosemicarbazones</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">123</span>:<span class="fpage" tagx="fpage" title="fpage">532</span>â€"<span class="lpage" tagx="lpage" title="lpage">43</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27517802">27517802</a></span></span></li> <li tag="ref"><a name="CIT0017" /><span class="label" tagx="label" title="label">17</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yin</span><span class="given-names" tagx="given-names" title="given-names">X</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yan</span><span class="given-names" tagx="given-names" title="given-names">W.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis and antimicrobial evaluation of propylene-tethered ciprofloxacin-isatin hybrids</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">156</span>:<span class="fpage" tagx="fpage" title="fpage">580</span>â€"<span class="lpage" tagx="lpage" title="lpage">6</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30025351">30025351</a></span></span></li> <li tag="ref"><a name="CIT0018" /><span class="label" tagx="label" title="label">18</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xu</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guan</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xu</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhao</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis and <i>inÂ vitro</i> anti-mycobacterial activities of homonuclear and heteronuclear bis-isatin derivatives</span>. <span class="source" tagx="source" title="source">Fitoterapia</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">127</span>:<span class="fpage" tagx="fpage" title="fpage">383</span>â€"<span class="lpage" tagx="lpage" title="lpage">6</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29631015">29631015</a></span></span></li> <li tag="ref"><a name="CIT0019" /><span class="label" tagx="label" title="label">19</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Akhaja</span><span class="given-names" tagx="given-names" title="given-names">TN</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Raval</span><span class="given-names" tagx="given-names" title="given-names">JP.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis, <i>inÂ vitro</i> evaluation of tetrahydropyrimidineâ€"isatin hybrids as potential antibacterial, antifungal and anti-tubercular agents</span>. <span class="source" tagx="source" title="source">Chin Chem Lett</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">23</span>:<span class="fpage" tagx="fpage" title="fpage">446</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.</span></li> <li tag="ref"><a name="CIT0020" /><span class="label" tagx="label" title="label">20</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Han</span><span class="given-names" tagx="given-names" title="given-names">YJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">QB</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xue</span><span class="given-names" tagx="given-names" title="given-names">LW.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis, crystal structure, and antibacterial activity of oxovanadium (V) complexes derived from N'-[1-(5-fluoro-2-hydroxyphenyl)methylidene]nicotinohydrazide and N'-(5-fluoro-2-hydroxy benzyli dene)-2-hydroxynaphthylhydrazide</span>. <span class="source" tagx="source" title="source">Russ J Coord Chem</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">43</span>:<span class="fpage" tagx="fpage" title="fpage">612</span>â€"<span class="lpage" tagx="lpage" title="lpage">8</span>.</span></li> <li tag="ref"><a name="CIT0021" /><span class="label" tagx="label" title="label">21</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Soliman</span><span class="given-names" tagx="given-names" title="given-names">DH</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ghabbour</span><span class="given-names" tagx="given-names" title="given-names">HA</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel 6-phenylnicotinohydrazide derivatives: design, synthesis and biological evaluation as a novel class of antitubercular and antimicrobial agents</span>. <span class="source" tagx="source" title="source">Biol Pharm Bull</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">40</span>:<span class="fpage" tagx="fpage" title="fpage">1883</span>â€"<span class="lpage" tagx="lpage" title="lpage">93</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29093335">29093335</a></span></span></li> <li tag="ref"><a name="CIT0022" /><span class="label" tagx="label" title="label">22</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Castelo-Branco</span><span class="given-names" tagx="given-names" title="given-names">FS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Lima</span><span class="given-names" tagx="given-names" title="given-names">EC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Domingos</span><span class="given-names" tagx="given-names" title="given-names">JLdO</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">New hydrazides derivatives of isoniazid against <i>Mycobacterium tuberculosis</i>: higher potency and lower hepatocytotoxicity</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">146</span>:<span class="fpage" tagx="fpage" title="fpage">529</span>â€"<span class="lpage" tagx="lpage" title="lpage">40</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29407978">29407978</a></span></span></li> <li tag="ref"><a name="CIT0023" /><span class="label" tagx="label" title="label">23</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gao</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yang</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lu</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis and anti-mycobacterial activity evaluation of benzofuran-isatin hybrids</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">159</span>:<span class="fpage" tagx="fpage" title="fpage">277</span>â€"<span class="lpage" tagx="lpage" title="lpage">81</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30296686">30296686</a></span></span></li> <li tag="ref"><a name="CIT0024" /><span class="label" tagx="label" title="label">24</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ma</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Ciprofloxacin-1,2,3-triazole-isatin hybrids tethered via amide: design, synthesis, and inÂ vitro anti-mycobacterial activity evaluation</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">29</span>:<span class="fpage" tagx="fpage" title="fpage">2635</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31358466">31358466</a></span></span></li> <li tag="ref"><a name="CIT0025" /><span class="label" tagx="label" title="label">25</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aboul-Fadl</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mohammed</span><span class="given-names" tagx="given-names" title="given-names">FAH</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hassan</span><span class="given-names" tagx="given-names" title="given-names">EAS.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis, antitubercular activity and pharmacokinetic studies of some schiff bases derived from 1-alkylisatin and isonicotinic acid hydrazide (inh)</span>. <span class="source" tagx="source" title="source">Arch Pharm Res</span><span class="year" tagx="year" title="year">2003</span>;<span class="volume" tagx="volume" title="volume">26</span>:<span class="fpage" tagx="fpage" title="fpage">778</span>â€"<span class="lpage" tagx="lpage" title="lpage">84</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/14609123">14609123</a></span></span></li> <li tag="ref"><a name="CIT0026" /><span class="label" tagx="label" title="label">26</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aboul-Fadl</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bin-Jubair</span><span class="given-names" tagx="given-names" title="given-names">FAS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aboul-Wafa</span><span class="given-names" tagx="given-names" title="given-names">O.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Schiff bases of indoline-2,3-dione (isatin) derivatives and nalidixic acid carbohydrazide, synthesis, antitubercular activity and pharmacophoric model building</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">45</span>:<span class="fpage" tagx="fpage" title="fpage">4578</span>â€"<span class="lpage" tagx="lpage" title="lpage">86</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20696500">20696500</a></span></span></li> <li tag="ref"><a name="CIT0027" /><span class="label" tagx="label" title="label">27</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abo-Ashour</span><span class="given-names" tagx="given-names" title="given-names">MF</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">George</span><span class="given-names" tagx="given-names" title="given-names">RF</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel indole-thiazolidinone conjugates: design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">160</span>:<span class="fpage" tagx="fpage" title="fpage">49</span>â€"<span class="lpage" tagx="lpage" title="lpage">60</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30317025">30317025</a></span></span></li> <li tag="ref"><a name="CIT0028" /><span class="label" tagx="label" title="label">28</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abo-Ashour</span><span class="given-names" tagx="given-names" title="given-names">MF</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">George</span><span class="given-names" tagx="given-names" title="given-names">RF</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and biological evaluation of 2-aminothiazole-thiazolidinone conjugates as potential antitubercular agents</span>. <span class="source" tagx="source" title="source">Future Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">10</span>:<span class="fpage" tagx="fpage" title="fpage">1405</span>â€"<span class="lpage" tagx="lpage" title="lpage">19</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29788758">29788758</a></span></span></li> <li tag="ref"><a name="CIT0029" /><span class="label" tagx="label" title="label">29</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Karali</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">GÃ¼rsoy</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kandemirli</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and structure-antituberculosis activity relationship of 1H-indole-2,3-dione derivatives</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2007</span>;<span class="volume" tagx="volume" title="volume">15</span>:<span class="fpage" tagx="fpage" title="fpage">5888</span>â€"<span class="lpage" tagx="lpage" title="lpage">904</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17561405">17561405</a></span></span></li> <li tag="ref"><a name="CIT0030" /><span class="label" tagx="label" title="label">30</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Borsari</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ferrari</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Venturelli</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Costi</span><span class="given-names" tagx="given-names" title="given-names">MP.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Target-based approaches for the discovery of new antimycobacterial drugs</span>. <span class="source" tagx="source" title="source">Drug Discov Today</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">22</span>:<span class="fpage" tagx="fpage" title="fpage">492</span>â€"<span class="lpage" tagx="lpage" title="lpage">502</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27663094">27663094</a></span></span></li> <li tag="ref"><a name="CIT0031" /><span class="label" tagx="label" title="label">31</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">RoÅ¾man</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">SosiÄ�</span><span class="given-names" tagx="given-names" title="given-names">I</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fernandez</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">A new â€˜golden ageâ€™ for the antitubercular target InhA</span>. <span class="source" tagx="source" title="source">Drug Discov Today</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">22</span>:<span class="fpage" tagx="fpage" title="fpage">492</span>â€"<span class="lpage" tagx="lpage" title="lpage">502</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27663094">27663094</a></span></span></li> <li tag="ref"><a name="CIT0032" /><span class="label" tagx="label" title="label">32</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hassan</span><span class="given-names" tagx="given-names" title="given-names">NW</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Saudi</span><span class="given-names" tagx="given-names" title="given-names">MN</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdel-Ghany</span><span class="given-names" tagx="given-names" title="given-names">YS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel pyrazine based anti-tubercular agents: design, synthesis, biological evaluation and in silico studies</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">96</span>:<span class="fpage" tagx="fpage" title="fpage">103610</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32028062">32028062</a></span></span></li> <li tag="ref"><a name="CIT0033" /><span class="label" tagx="label" title="label">33</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tunney</span><span class="given-names" tagx="given-names" title="given-names">MM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ramage</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Field</span><span class="given-names" tagx="given-names" title="given-names">TR</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Rapid colorimetric assay for antimicrobial susceptibility testing of <i>Pseudomonas aeruginosa</i></span>. <span class="source" tagx="source" title="source">Antimicrob Agents Chemother</span><span class="year" tagx="year" title="year">2004</span>;<span class="volume" tagx="volume" title="volume">48</span>:<span class="fpage" tagx="fpage" title="fpage">1879</span>â€"<span class="lpage" tagx="lpage" title="lpage">81</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15105149">15105149</a></span></span></li> <li tag="ref"><a name="CIT0034" /><span class="label" tagx="label" title="label">34</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fathallah</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Raafat</span><span class="given-names" tagx="given-names" title="given-names">MM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Issa</span><span class="given-names" tagx="given-names" title="given-names">MY</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Bio-guided fractionation of prenylated benzaldehyde derivatives as potent antimicrobial and antibiofilm from <i>Ammi majus</i> L. fruits-associated <i>Aspergillus amstelodami</i></span>. <span class="source" tagx="source" title="source">Molecules</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">24</span>:<span class="fpage" tagx="fpage" title="fpage">4118</span>â€"<span class="lpage" tagx="lpage" title="lpage">24</span>.</span></li> <li tag="ref"><a name="CIT0035" /><span class="label" tagx="label" title="label">35</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Finger</span><span class="given-names" tagx="given-names" title="given-names">GC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Starr</span><span class="given-names" tagx="given-names" title="given-names">LD</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Roe</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Link</span><span class="given-names" tagx="given-names" title="given-names">WJ.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Aromatic fluorine compounds. X. The 2, 3-and 2, 6-difluoropyridines</span>. <span class="source" tagx="source" title="source">J Org Chem</span><span class="year" tagx="year" title="year">1962</span>;<span class="volume" tagx="volume" title="volume">27</span>:<span class="fpage" tagx="fpage" title="fpage">3965</span>â€"<span class="lpage" tagx="lpage" title="lpage">8</span>.</span></li> <li tag="ref"><a name="CIT0036" /><span class="label" tagx="label" title="label">36</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fares</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ibrahim</span><span class="given-names" tagx="given-names" title="given-names">HS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and cytotoxic activity of biphenylurea derivatives containing indolin-2-one moieties</span>. <span class="source" tagx="source" title="source">Molecules</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">21</span>:<span class="fpage" tagx="fpage" title="fpage">762</span>.</span></li> <li tag="ref"><a name="CIT0037" /><span class="label" tagx="label" title="label">37</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Attia</span><span class="given-names" tagx="given-names" title="given-names">MI</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Afifi</span><span class="given-names" tagx="given-names" title="given-names">SA</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">New hydrazonoindolin-2-ones: synthesis, exploration of the possible anti-proliferative mechanism of action and encapsulation into PLGA microspheres</span>. <span class="source" tagx="source" title="source">PLoS One</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">12</span>:<span class="fpage" tagx="fpage" title="fpage">e0181241</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28742842">28742842</a></span></span></li> <li tag="ref"><a name="CIT0038" /><span class="label" tagx="label" title="label">38</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hassan</span><span class="given-names" tagx="given-names" title="given-names">GS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Rashood</span><span class="given-names" tagx="given-names" title="given-names">ST</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and <i>inÂ vitro</i> anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents</span>. <span class="source" tagx="source" title="source">J Enzyme Inhib Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">34</span>:<span class="fpage" tagx="fpage" title="fpage">322</span>â€"<span class="lpage" tagx="lpage" title="lpage">32</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30722708">30722708</a></span></span></li> <li tag="ref"><a name="CIT0039" /><span class="label" tagx="label" title="label">39</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Luk</span><span class="given-names" tagx="given-names" title="given-names">K-C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">So</span><span class="given-names" tagx="given-names" title="given-names">S-S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">Z.</span></span></span> Oxindole derivatives, Patent 7576082, USA; <span class="year" tagx="year" title="year">2009</span>.</span></li> <li tag="ref"><a name="CIT0040" /><span class="label" tagx="label" title="label">40</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mosmann</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays</span>. <span class="source" tagx="source" title="source">J Immunol Methods</span><span class="year" tagx="year" title="year">1983</span>;<span class="volume" tagx="volume" title="volume">65</span>:<span class="fpage" tagx="fpage" title="fpage">55</span>â€"<span class="lpage" tagx="lpage" title="lpage">63</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/6606682">6606682</a></span></span></li> <li tag="ref"><a name="CIT0041" /><span class="label" tagx="label" title="label">41</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ismail</span><span class="given-names" tagx="given-names" title="given-names">RS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abou-Seri</span><span class="given-names" tagx="given-names" title="given-names">SM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">155</span>:<span class="fpage" tagx="fpage" title="fpage">782</span>â€"<span class="lpage" tagx="lpage" title="lpage">96</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30047410">30047410</a></span></span></li> <li tag="ref"><a name="CIT0042" /><span class="label" tagx="label" title="label">42</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Makarov</span><span class="given-names" tagx="given-names" title="given-names">V</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lechartier</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Towards a new combination therapy for tuberculosis with next generation benzothiazinones</span>. <span class="source" tagx="source" title="source">EMBO Mol Med</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">6</span>:<span class="fpage" tagx="fpage" title="fpage">372</span>â€"<span class="lpage" tagx="lpage" title="lpage">83</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24500695">24500695</a></span></span></li> <li tag="ref"><a name="CIT0043" /><span class="label" tagx="label" title="label">43</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sullivan</span><span class="given-names" tagx="given-names" title="given-names">TJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Truglio</span><span class="given-names" tagx="given-names" title="given-names">JJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Boyne</span><span class="given-names" tagx="given-names" title="given-names">ME</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">High affinity InhA inhibitors with activity against drug-resistant strains of <i>Mycobacterium tuberculosis</i></span>. <span class="source" tagx="source" title="source">ACS Chem Biol</span><span class="year" tagx="year" title="year">2006</span>;<span class="volume" tagx="volume" title="volume">1</span>:<span class="fpage" tagx="fpage" title="fpage">43</span>â€"<span class="lpage" tagx="lpage" title="lpage">53</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17163639">17163639</a></span></span></li> <li tag="ref"><a name="CIT0044" /><span class="label" tagx="label" title="label">44</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Trott</span><span class="given-names" tagx="given-names" title="given-names">O</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Olson</span><span class="given-names" tagx="given-names" title="given-names">AJ.</span></span></span><span class="mixed-article-title" title="mixed-article-title">AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span>. <span class="source" tagx="source" title="source">J Comput Chem</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">31</span>:<span class="fpage" tagx="fpage" title="fpage">455</span>â€"<span class="lpage" tagx="lpage" title="lpage">61</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19499576">19499576</a></span></span></li> <li tag="ref"><a name="CIT0045" /><span class="label" tagx="label" title="label">45</span><span class="element-citation'"><a href="https://3dsbiovia.com/resource-center/downloads/">https://3dsbiovia.com/resource-center/downloads/</a></span></li> </ul> </div> </div>  </body></html>